AACR 2024 | The clinical applications of MRD in breast cancer

Mitchell Elliott, MD, UHN Princess Margaret Cancer Centre, Toronto, Canada, describes advances in minimal residual disease (MRD) for breast cancer. MRD can be utilized to enable de-escalation of radiographic surveillance in certain patients, benefiting patients and clinicians by saving resources and times. Having the ability to assessing novel mutations in the tumor is additionally a benefit of MRD assessment, as shown in the PADA-1 trial (NCT03079011). This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.